Mineralys Therapeutics, Inc. $MLYS Shares Purchased by Suvretta Capital Management LLC

Suvretta Capital Management LLC increased its position in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) by 22.2% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,132,133 shares of the company’s stock after buying an additional 387,641 shares during the period. Mineralys Therapeutics accounts for 2.1% of Suvretta Capital Management LLC’s holdings, making the stock its 12th biggest position. Suvretta Capital Management LLC owned about 2.69% of Mineralys Therapeutics worth $80,850,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Wellington Management Group LLP increased its holdings in Mineralys Therapeutics by 578.6% in the third quarter. Wellington Management Group LLP now owns 783,445 shares of the company’s stock valued at $29,708,000 after buying an additional 667,997 shares in the last quarter. FORA Capital LLC purchased a new stake in shares of Mineralys Therapeutics during the 3rd quarter worth about $240,000. Invesco Ltd. boosted its stake in shares of Mineralys Therapeutics by 630.2% during the 3rd quarter. Invesco Ltd. now owns 187,986 shares of the company’s stock worth $7,128,000 after acquiring an additional 162,243 shares in the last quarter. Sei Investments Co. acquired a new stake in shares of Mineralys Therapeutics during the 3rd quarter valued at about $374,000. Finally, Atika Capital Management LLC acquired a new stake in shares of Mineralys Therapeutics during the 3rd quarter valued at about $6,598,000. Institutional investors and hedge funds own 84.46% of the company’s stock.

Trending Headlines about Mineralys Therapeutics

Here are the key news stories impacting Mineralys Therapeutics this week:

• Positive Sentiment: NDA accepted by FDA and PDUFA set (Dec. 22, 2026) for lorundrostat — formal regulatory review underway, which de-risks timing for potential approval and commercialization. GlobeNewswire: Q4 results & NDA acceptance
• Positive Sentiment: Q4 results surprised to the upside — reported EPS of ($0.40) vs. consensus ($0.57), suggesting operational execution beat expectations and reducing near-term downside to estimates. MarketBeat: Q4 earnings summary
• Positive Sentiment: Management is actively preparing for launch and payer engagement ahead of the regulatory decision — signaling commercialization planning and market-access work that could speed uptake if approved. Seeking Alpha: Launch & payer engagement
• Neutral Sentiment: Conference call and transcript provide management’s roadmap and data context (Q4 call reviewed NDA strategy, clinical data and next steps); useful for modeling but not a surprise item. Seeking Alpha: Earnings call transcript
• Neutral Sentiment: Press coverage highlights steady progress with FDA interactions and public messaging; these articles reiterate facts rather than deliver new catalysts. Yahoo Finance: FDA progress TipRanks: NDA acceptance overview
• Negative Sentiment: Critical commentary warns of potential interference from larger pharma interests that could complicate the approval or market dynamics — introduces regulatory and competitive risk that can pressure shares. Seeking Alpha: Concerns over big pharma pressure

Mineralys Therapeutics Trading Down 3.0%

Shares of Mineralys Therapeutics stock opened at $26.19 on Friday. The firm has a market capitalization of $2.07 billion, a PE ratio of -11.05 and a beta of 0.57. Mineralys Therapeutics, Inc. has a twelve month low of $10.44 and a twelve month high of $47.65. The firm’s 50-day moving average price is $30.45 and its 200 day moving average price is $35.37.

Mineralys Therapeutics (NASDAQ:MLYS) last posted its quarterly earnings data on Thursday, March 12th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.17. On average, sell-side analysts predict that Mineralys Therapeutics, Inc. will post -4.23 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

MLYS has been the subject of a number of analyst reports. Wall Street Zen cut Mineralys Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. HC Wainwright set a $56.00 price objective on Mineralys Therapeutics and gave the company a “buy” rating in a report on Tuesday. Bank of America boosted their price objective on Mineralys Therapeutics from $46.00 to $51.00 and gave the company a “buy” rating in a research report on Friday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Mineralys Therapeutics in a research note on Thursday, January 22nd. Finally, Jefferies Financial Group reissued a “hold” rating and issued a $30.00 price target on shares of Mineralys Therapeutics in a research note on Friday. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $49.14.

Insider Transactions at Mineralys Therapeutics

In related news, CFO Adam Scott Levy sold 10,758 shares of the business’s stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $32.14, for a total transaction of $345,762.12. Following the completion of the sale, the chief financial officer directly owned 8,638 shares in the company, valued at approximately $277,625.32. The trade was a 55.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Jon Congleton sold 16,236 shares of the stock in a transaction on Monday, January 12th. The shares were sold at an average price of $32.62, for a total value of $529,618.32. Following the completion of the transaction, the chief executive officer directly owned 639,151 shares of the company’s stock, valued at approximately $20,849,105.62. This represents a 2.48% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 342,919 shares of company stock valued at $11,755,439 over the last ninety days. Insiders own 25.56% of the company’s stock.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.